GERMANTOWN, Maryland and HILDEN, Germany, May 26, 2010 /PRNewswire-FirstCall/ -- QIAGEN N.V. (NASDAQ: QGEN [ http://quotes.nasdaq.com/asp/SummaryQuote.asp?symbol=QGEN&selected=QGEN ]; Frankfurt, Prime Standard: QIA [ http://www.boerse-frankfurt.de/DE/index.aspx?pageID=35&ISIN=NL0000240000 ]) today announced that it has signed an agreement with Roche Molecular Systems Inc., a unit of Roche Holding AG (ROG.VX [ http://www.reuters.com/finance/stocks/overview?symbol=ROG.VX ]), resolving a dispute over distribution rights for a set of companion diagnostic products developed and manufactured by QIAGEN's Manchester subsidiary DxS Ltd. Subsequently, the parties withdrew their claims filed against one another in the action that was pending in the US District Court for the Southern District of New York.
Under the terms of the agreement, Roche maintained its rights to
distribute the two assays it currently distributes (KRAS and EGFR) under the
DxS TheraScreen(R) label and, under certain conditions, to distribute future
versions thereof. QIAGEN obtained rights to distribute these assays under the
QIAGEN label and also obtained exclusive distribution rights for all other
assays, including future assays, developed
Copyright©2010 PR Newswire.
All rights reserved